AG真人官方

Call Scheduled for Thursday, May 15, 2025 at 5:00 pm ET

LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (鈥淰ivos鈥� or the 鈥淐ompany鈥�) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 鈥� 17)), today announced it plans to release its first quarter 2025 financial results after market close on Thursday, May 15, 2025. The Company will conduct a conference call at 5:00 p.m. (Eastern Time) on May 15, 2025 to review the results and provide an overview of the Company鈥檚 recent milestones and developments.

To access Vivos鈥� investor conference call, please dial (800) 717-1738, or for international callers, (646) 307-1865. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the replay is 1124460. The replay will be available until May 29, 2025.

A live webcast of the conference call can be accessed on Vivos鈥� website at . An online archive of the webcast will be available on the Company鈥檚 website for 30 days following the call.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos鈥� devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos鈥� groundbreaking CARE devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children.听

Obstructive sleep apnea (OSA) affects over 1 billion people worldwide, yet 90% remain undiagnosed and unaware of their condition. This chronic disorder is not just a sleep issue鈥攊t鈥檚 closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, solutions are often mechanistic and fail to address the root causes of OSA.听

Vivos Therapeutics, founded in 2016 and based in Littleton, CO, is changing this. Through innovative technology, education, and partnerships with dentists, functional medicine doctors, and sleep specialists, Vivos is empowering healthcare providers to more thoroughly address the complex needs of patients.

The Vivos Method offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life. For more information, visit www.vivos.com.听

Cautionary Note Regarding Forward-Looking Statements

This press release, the conference call referred to herein, and statements of the Company鈥檚 management and other parties made herein, contain 鈥渇orward-looking statements鈥� (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as 鈥渕ay鈥�, 鈥渨ould鈥�, 鈥渟hould鈥�, 鈥渆xpects鈥�, 鈥減rojects,鈥� 鈥減otential,鈥� 鈥渋ntends鈥�, 鈥減lans鈥�, 鈥渂elieves鈥�, 鈥渁nticipates鈥�, 鈥渉opes鈥�, 鈥渆stimates鈥�, 鈥済oal鈥�. 鈥渁im鈥� and variations of such words and similar expressions are intended to identify forward-looking statements. In this press release, forward-looking statements include, without limitation, those relating to (i) the timing for closing of the SCN acquisition (which remains subject to key conditions such as financing), (ii) the actual future impact of the SCN acquisition on Vivos鈥� future revenues and results of operations and (ii) the anticipated benefits and potential expansion of Vivos鈥� marketing and distribution model as described herein. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos鈥� control. Actual results (including the actual future impact of the initiatives and corporate achievements described herein on Vivos鈥� future revenues and results of operations and the anticipated benefits of the Company鈥檚 new marketing and distribution model described herein). Readers are cautioned that actual results may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to finance the cash portion of the acquisition purchase price on favorable terms, if at all, or otherwise, (ii) the risk that Vivos may be unable to successfully integrate SCN鈥檚 business into its own or otherwise implement sales, marketing and other strategies that increase revenues, (iii) the risk that some patients may not achieve the desired results from using Vivos鈥� products, (iv) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea diagnosis and treatment sector; (v) the risk that Vivos may be unable to secure additional financing beyond that which is needed to acquire SCN on reasonable terms when needed, if at all, or maintain its Nasdaq listing, (vi) market and other conditions that could impact Vivos鈥� business or ability to obtain financing, and (vii) other risk factors described in Vivos鈥� filings with the Securities and Exchange Commission (鈥淪EC鈥�). Vivos鈥� filings can be obtained free of charge on the SEC鈥檚 website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos鈥� expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.

Vivos Investor Relations:
Bradford Amman
Chief Financial Officer and Investor Relations Contact
听